These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 8956160)

  • 1. Chiasmal herniation as a complication of bromocriptine therapy.
    Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
    J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
    Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
    Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
    Jones SE; James RA; Hall K; Kendall-Taylor P
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her vision was tied down.
    Dorotheo EU; Tang RA; Bahrani HM; Schiffman JS; Bhatti MT; Lewis SB
    Surv Ophthalmol; 2005; 50(6):588-97. PubMed ID: 16263371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
    Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
    Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
    Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endonasal endoscopic transsphenoidal chiasmapexy using a clival cranial base cranioplasty for visual loss from massive empty sella following macroprolactinoma treatment with bromocriptine: case report.
    Alvarez Berastegui GR; Raza SM; Anand VK; Schwartz TH
    J Neurosurg; 2016 Apr; 124(4):1025-31. PubMed ID: 26339851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Untethering of herniated left optic nerve after dopamine agonist treatment for giant prolactinoma.
    Gkekas N; Primikiris P; Georgakoulias N
    Acta Neurochir (Wien); 2013 Mar; 155(3):495-6. PubMed ID: 23314935
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blurred vision during airline flight reveals prolactinoma.
    Bodack MI
    Optometry; 2003 Mar; 74(3):159-72. PubMed ID: 12645849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic transsphenoidal treatment of a prolactinoma patient with brain and optic chiasmal herniations.
    Zhang N; Guo L; Ge J; Qiu Y
    J Craniofac Surg; 2014 May; 25(3):e271-2. PubMed ID: 24820730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of macroprolactinomas with delayed bromocriptine. Effectiveness of a single intramuscular injection].
    García-Luna PP; Leal-Cerro A; Pereira JL; Navarro E; Trujillo F; Cortés A; Villamil F; Acosta D; Santos C; Revuelta M
    Med Clin (Barc); 1990 Feb; 94(4):126-9. PubMed ID: 2325463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
    Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
    Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncommon chiasmal lesions: demyelinating disease, vasculitis, and cobalamin deficiency.
    Wilhelm H; Grodd W; Schiefer U; Zrenner E
    Ger J Ophthalmol; 1993 Aug; 2(4-5):234-40. PubMed ID: 8220105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Macroprolactinoma resistant to bromocriptine].
    López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
    Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.